rct
    2011
    High Quality

    Selenium and Vitamin E Cancer Prevention Trial (SELECT): null and adverse findings

    Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH

    Published in JAMA

    Methodology

    Randomized placebo-controlled prevention trial of selenium and vitamin E in 35,533 men followed for a median of 7 years.

    Key Findings

    Vitamin E supplementation significantly increased prostate cancer risk by 17%, and selenium provided no protective benefit.

    Conclusions

    High-quality null and harm evidence against antioxidant supplementation for cancer prevention.

    Limitations

    Healthy men only; single dose regimens.

    Supplements Studied

    Selenium
    Mineral

    Selenium provided no protective benefit against prostate cancer

    Vitamin E
    Vitamin

    Vitamin E supplementation significantly increased prostate cancer risk by 17%

    Outcomes Measured

    Tumor Response Rate

    Vitamin E supplementation significantly increased prostate cancer risk by 17%, and selenium provided no protective benefit

    UV Protection

    Vitamin E supplementation significantly increased prostate cancer risk by 17%

    Related Health Concerns

    Cancer
    Prostate Cancer

    Study Details

    Year:2011
    Sample Size:35,533
    Duration:364 weeks
    Quality Score:10/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.